Literature DB >> 30506481

The impact of biventricular heart failure on outcomes after transcatheter aortic valve implantation.

Tobias Schmidt1, Mintje Bohné2, Michael Schlüter3, Mitsunobu Kitamura2, Peter Wohlmuth3, Dimitry Schewel2, Jury Schewel2, Michael Schmoeckel4, Karl-Heinz Kuck2, Christian Frerker2.   

Abstract

AIMS: We sought to assess the impact of different manifestations of heart failure (HF) at baseline on the short- and long-term outcomes of transcatheter aortic valve implantation (TAVI) for aortic stenosis (AS). METHODS AND
RESULTS: Of 361 patients undergoing TAVI between May 2013 and April 2015, 185 (51%) showed clinical signs of HF at the time of admission. HF was diagnosed as isolated left ventricular (LV) and biventricular in 63 (34%) and 122 patients (66%), respectively. Acute device success (VARC-2) was achieved in 97% of patients without HF, in all patients with LV HF, and in 97% of patients with biventricular HF. Follow-up for a median of 427 days revealed significantly poorer survival in patients with biventricular HF (1-year estimate, 72.1% [95% confidence interval, 64.0-80.2%]) than in patients with LV HF (84.5% [75.2-93.8%]; p = 0.0203) or no HF (94.3% [90.7-97.9%]; p < 0.0001). Survival in the latter two patient subgroups was statistically not different. A diagnosis of biventricular HF was associated with a hazard ratio of 2.62 (p = 0.0089) vs. no HF in the likelihood of death; NT-proBNP and the logistic EuroSCORE were not significantly associated with survival. Half of all deaths in patients with biventricular HF occurred within 42 days of TAVI.
CONCLUSION: Biventricular HF is a strong predictor of mortality following TAVI for severe AS. AS in patients with LV HF should be treated without delay to avoid progression to biventricular HF. Patients with AS and biventricular HF should be monitored closely after TAVI to possibly prevent early death.

Entities:  

Keywords:  Acute and long-term outcome; Heart failure; TAVI

Mesh:

Year:  2018        PMID: 30506481     DOI: 10.1007/s00392-018-1400-6

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  28 in total

1.  Transcatheter aortic valve implantation in patients with severe left ventricular dysfunction: immediate and mid-term results, a multicenter study.

Authors:  Chiara Fraccaro; Rasha Al-Lamee; Giuseppe Tarantini; Francesco Maisano; Massimo Napodano; Matteo Montorfano; Anna Chiara Frigo; Sabino Iliceto; Gino Gerosa; Giambattista Isabella; Antonio Colombo
Journal:  Circ Cardiovasc Interv       Date:  2012-04-10       Impact factor: 6.546

2.  Prognostic importance of quantitative exercise Doppler echocardiography in asymptomatic valvular aortic stenosis.

Authors:  Patrizio Lancellotti; Florence Lebois; Marc Simon; Christophe Tombeux; Christophe Chauvel; Luc A Pierard
Journal:  Circulation       Date:  2005-08-30       Impact factor: 29.690

Review 3.  Should elderly patients be admitted to the intensive care unit?

Authors:  Ariane Boumendil; Dominique Somme; Maïté Garrouste-Orgeas; Bertrand Guidet
Journal:  Intensive Care Med       Date:  2007-04-03       Impact factor: 17.440

4.  Transcatheter versus surgical aortic-valve replacement in high-risk patients.

Authors:  Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

5.  Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study.

Authors:  Eberhard Grube; Jean C Laborde; Ulrich Gerckens; Thomas Felderhoff; Barthel Sauren; Lutz Buellesfeld; Ralf Mueller; Maurizio Menichelli; Thomas Schmidt; Bernfried Zickmann; Stein Iversen; Gregg W Stone
Journal:  Circulation       Date:  2006-10-02       Impact factor: 29.690

6.  Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up.

Authors:  Patricia A Pellikka; Maurice E Sarano; Rick A Nishimura; Joseph F Malouf; Kent R Bailey; Christopher G Scott; Marion E Barnes; A Jamil Tajik
Journal:  Circulation       Date:  2005-06-13       Impact factor: 29.690

7.  Natural history of very severe aortic stenosis.

Authors:  Raphael Rosenhek; Robert Zilberszac; Michael Schemper; Martin Czerny; Gerald Mundigler; Senta Graf; Jutta Bergler-Klein; Michael Grimm; Harald Gabriel; Gerald Maurer
Journal:  Circulation       Date:  2009-12-21       Impact factor: 29.690

8.  Predictors of outcome in severe, asymptomatic aortic stenosis.

Authors:  R Rosenhek; T Binder; G Porenta; I Lang; G Christ; M Schemper; G Maurer; H Baumgartner
Journal:  N Engl J Med       Date:  2000-08-31       Impact factor: 91.245

9.  Usefulness of exercise-stress echocardiography for risk stratification of true asymptomatic patients with aortic valve stenosis.

Authors:  Sylvestre Maréchaux; Zeineb Hachicha; Annaïk Bellouin; Jean G Dumesnil; Patrick Meimoun; Agnès Pasquet; Sébastien Bergeron; Marie Arsenault; Thierry Le Tourneau; Pierre Vladimir Ennezat; Philippe Pibarot
Journal:  Eur Heart J       Date:  2010-03-21       Impact factor: 29.983

10.  Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis.

Authors:  Jutta Bergler-Klein; Ursula Klaar; Maria Heger; Raphael Rosenhek; Gerald Mundigler; Harald Gabriel; Thomas Binder; Richard Pacher; Gerald Maurer; Helmut Baumgartner
Journal:  Circulation       Date:  2004-04-26       Impact factor: 29.690

View more
  1 in total

1.  Outcome of patients with heart failure after transcatheter aortic valve implantation.

Authors:  Ulrich Fischer-Rasokat; Matthias Renker; Christoph Liebetrau; Maren Weferling; Andreas Rolf; Mirko Doss; Helge Möllmann; Thomas Walther; Christian W Hamm; Won-Keun Kim
Journal:  PLoS One       Date:  2019-11-26       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.